XML 35 R18.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Goodwill and Intangible Assets, Net | 9 Months Ended
--- | ---
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets, Net | Goodwill and Intangible Assets, Net Changes in the carrying amount of goodwill were as follows:
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Total
Balance, March 31, 2019 | $ | 4,078 |  |  | $ | — |  |  | $ | 2,451 |  |  | $ | 2,829 |  |  | $ | 9,358 |
Goodwill acquired | — |  |  | 56 |  |  | — |  |  | — |  |  | 56 |
Acquisition accounting, transfers and other adjustments | 1 |  |  | 4 |  |  | 7 |  |  | — |  |  | 12 |
Other changes/disposals | (1 | ) |  | — |  |  | (5 | ) |  | — |  |  | (6 | )
Impairment charges | — |  |  | — |  |  | — |  |  | (2 | ) |  | (2 | )
Foreign currency translation adjustments, net | — |  |  | 3 |  |  | — |  |  | 35 |  |  | 38 |
Balance, December 31, 2019 | $ | 4,078 |  |  | $ | 63 |  |  | $ | 2,453 |  |  | $ | 2,862 |  |  | $ | 9,456 |
Information regarding intangible assets is as follows:
| December 31, 2019 |  | March 31, 2019
(Dollars in millions) | Weighted Average Remaining Amortization Period (Years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Customer relationships | 11 |  | $ | 3,602 |  |  | $ | (1,792 | ) |  | $ | 1,810 |  |  | $ | 3,818 |  |  | $ | (1,801 | ) |  | $ | 2,017 |
Service agreements | 10 |  | 1,023 |  |  | (479 | ) |  | 544 |  |  | 1,017 |  |  | (430 | ) |  | 587 |
Pharmacy licenses | 26 |  | 517 |  |  | (229 | ) |  | 288 |  |  | 513 |  |  | (209 | ) |  | 304 |
Trademarks and trade names | 13 |  | 833 |  |  | (235 | ) |  | 598 |  |  | 887 |  |  | (232 | ) |  | 655 |
Technology | 4 |  | 173 |  |  | (108 | ) |  | 65 |  |  | 141 |  |  | (94 | ) |  | 47 |
Other | 5 |  | 278 |  |  | (219 | ) |  | 59 |  |  | 288 |  |  | (209 | ) |  | 79 |
Total |  |  | $ | 6,426 |  |  | $ | (3,062 | ) |  | $ | 3,364 |  |  | $ | 6,664 |  |  | $ | (2,975 | ) |  | $ | 3,689 |
Amortization expense of intangible assets was $113 million and $343 million for the three and nine months ended December 31, 2019 and $122 million and $365 million for the three and nine months ended December 31, 2018. Estimated amortization expense of these assets is as follows: $118 million, $449 million, $357 million, $259 million and $242 million for the remainder of 2020 and each of the succeeding years through 2024 and $1.9 billion thereafter. All intangible assets were subject to amortization as of December 31, 2019 and March 31, 2019. During the nine months ended December 31, 2019 and 2018, the Company recorded impairments related to certain intangible assets in its European Pharmaceutical Solutions segment and its Rexall Health retail business within Other. Refer to Financial Note 4, “Restructuring, Impairment and Related Charges” for more information.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration